BlossomHill Therapeutics (NASDAQ:BLSM) Now Covered by Lifesci Capital

Lifesci Capital began coverage on shares of BlossomHill Therapeutics (NASDAQ:BLSM) in a research note issued on Tuesday, Benzinga reports. The brokerage set an “outperform” rating and a $32.00 price target on the stock. Lifesci Capital’s price target points to a potential upside of 72.41% from the company’s current price.

BLSM has been the subject of several other reports. JPMorgan Chase & Co. assumed coverage on shares of BlossomHill Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $28.00 price target for the company. HC Wainwright initiated coverage on BlossomHill Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $35.00 target price for the company. Guggenheim assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $30.00 target price for the company. Wall Street Zen raised BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Finally, Leerink Partners set a $36.00 price target on BlossomHill Therapeutics and gave the stock an “outperform” rating in a report on Tuesday. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, BlossomHill Therapeutics has an average rating of “Buy” and a consensus price target of $32.20.

BlossomHill Therapeutics Trading Up 1.4%

Shares of BlossomHill Therapeutics stock traded up $0.26 during trading on Tuesday, reaching $18.56. 84,527 shares of the company traded hands, compared to its average volume of 222,985. BlossomHill Therapeutics has a 1-year low of $15.25 and a 1-year high of $20.61.

Insider Activity

In other BlossomHill Therapeutics news, Director Carl L. Gordon acquired 625,000 shares of the stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares in the company, valued at approximately $43,428,464. This represents a 29.91% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John P. Schmid acquired 6,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $96,000.00. Following the completion of the purchase, the director directly owned 6,000 shares of the company’s stock, valued at approximately $96,000. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 1,573,900 shares of company stock valued at $25,181,900.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.